Oxaliplatin Accord

Oxaliplatin, the active ingredient in Oxaliplatin Accord, is a platinum‑based chemotherapy agent presented as a sterile solution for intravenous infusion use. It is employed in the treatment of colorectal cancer and other solid tumours, typically in adult patients. GNH USA supplies Oxaliplatin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin Accord is used in colorectal cancer treatment protocols that target DNA replication pathways. - Colorectal cancer: Enhances tumor response when combined with fluoropyrimidine‑based regimens. - Gastric cancer: Contributes to tumor shrinkage as part of combination chemotherapy. - Pancreatic cancer: Used off‑label in some regimens to improve response rates.

Oxaliplatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Peripheral neuropathy: Tingling or numbness, often dose‑related. - Nausea and vomiting: Frequently experienced during or after infusion. - Diarrhea: May range from mild to moderate severity. - Fatigue: Generalised tiredness common during treatment cycles. - Thrombocytopenia: Reduced platelet count observed in blood tests.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: Including anaphylaxis, requiring immediate medical attention. - Acute hemolytic anemia: Rapid destruction of red blood cells. - Persistent neutropenia: Prolonged low neutrophil count increasing infection risk. - Pulmonary toxicity: Interstitial lung disease or pneumonitis. - Cardiac arrhythmias: Uncommon but potentially life‑threatening rhythm disturbances.

When handling Oxaliplatin Accord, clinicians should observe several safety measures. - Renal function monitoring: Assess baseline and periodic creatinine levels. - Hepatic function monitoring: Check liver enzymes before each cycle. - Neurotoxicity vigilance: Evaluate sensory symptoms before each infusion. - Hematologic surveillance: Perform complete blood counts regularly. - Premedication: Consider anti‑emetic prophylaxis to reduce nausea. - Store at ambient temperature: Keep vials in original packaging, protect from light and moisture.

Oxaliplatin may interact with several concomitant medications, altering efficacy or safety.

Major Interactions (Avoid): - Aminoglycoside antibiotics: May increase nephrotoxic risk. - High‑dose vitamin C: Can reduce platinum‑DNA binding effectiveness.

Moderate Interactions (Monitor Closely): - Anticoagulants anticoagulants: May heighten bleeding risk due to thrombocytopenia. - NSAIDs: Potentially exacerbate renal impairment. - Other neurotoxic agents: May compound peripheral neuropathy. - Strong CYP3A4 inducers: May affect plasma levels of co‑administered drugs. - Proton pump inhibitors: May alter gastric pH and affect oral supportive care agents.